Patents Assigned to Bio-Technology General (Israel) Ltd.
  • Patent number: 9896518
    Abstract: Manufactured hyaluronic acid products are used in numerous surgical applications including viscoelastic supplementation for the treatment of osteoarthritis, however, traditional sterilization techniques result in the breakdown of such high molecular o weight viscoelastic biopolymers and are thus unsuitable. Disclosed are processes for obtaining concentrated sterile solutions of high molecular weight biopolymers such as hyaluronic acid. The processes include filter sterilization with a dilute preparation of the biopolymer, and concentration of the dilute filter sterilized biopolymer by ultrafiltration to a desired concentration.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: February 20, 2018
    Assignee: Bio-Technology General (Israel) Ltd.
    Inventors: Menakem Fuchs, Dror Eyal, Yehuda Zelig
  • Publication number: 20140018315
    Abstract: Manufactured hyaluronic acid products are used in numerous surgical applications including viscoelastic supplementation for the treatment of osteoarthritis, however, traditional sterilization techniques result in the breakdown of such high molecular o weight viscoelastic biopolymers and are thus unsuitable. Disclosed are processes for obtaining concentrated sterile solutions of high molecular weight biopolymers such as hyaluronic acid. The processes include filter sterilization with a dilute preparation of the biopolymer, and concentration of the dilute filter sterilized biopolymer by ultrafiltration to a desired concentration.
    Type: Application
    Filed: September 10, 2013
    Publication date: January 16, 2014
    Applicant: Bio-Technology General (Israel) Ltd.
    Inventors: Menakem Fuchs, Dror Eyal, Yehuda Zelig
  • Publication number: 20140005141
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 2, 2014
    Applicants: Bio-Technology General (Israel) Ltd., Prochon Biotech Ltd.
    Inventors: Boaz AMIT, Avraham Wortzel, Avner YAYON
  • Patent number: 8524885
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: September 3, 2013
    Assignees: Prochon Biotech Ltd., Bio-Technology General (Israel) Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Publication number: 20110130473
    Abstract: Manufactured hyaluronic acid products are used in numerous surgical applications including viscoelastic supplementation for the treatment of osteoarthritis, however, traditional sterilization techniques result in the breakdown of such high molecular weight viscoelastic biopolymers and are thus unsuitable. Disclosed are processes for obtaining concentrated sterile solutions of high molecular weight biopolymers such as hyaluronic acid. The processes include filter sterilization with a dilute preparation of the biopolymer, and concentration of the dilute filter sterilized biopolymer by ultrafiltration to a desired concentration.
    Type: Application
    Filed: November 12, 2008
    Publication date: June 2, 2011
    Applicant: Bio-Technology General (Israel) Ltd.
    Inventors: Menakem Fuchs, Dror Eyal, Yehuda Zelig
  • Publication number: 20090149419
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Application
    Filed: March 6, 2007
    Publication date: June 11, 2009
    Applicants: PROCHON BIOTECH LTD., Bio-Technology General (Israel) Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Patent number: 7132510
    Abstract: The present invention is directed to novel peptides and polypeptides that specifically bind to target cells and may have anti-cancer activity, especially blood-related cancers. The present invention includes a peptide or polypeptide comprising an Fv molecule, having a heavy variable chain comprising CDR3, CDR2 and CDR1 regions comprising the amino acid sequences SEQ ID NOS:8, 115 and 114, respectively.
    Type: Grant
    Filed: December 31, 2001
    Date of Patent: November 7, 2006
    Assignee: Bio-Technology General (Israel) Ltd.
    Inventors: Yocheved Hagay, Janette Lazarovits, Rachel Guy, Orly Lifshitz, Esther Szanton, Avigdor Levanon, Daniel Plaksin, Tuvia Peretz